The efficacy and safety of the new GLP-1 medicines continues to garner interest and will be discussed #ADA2024 Here is an updated safety-focused summary of the field and where it might be headed @DiabetesCareADA #T2D #obesity pic.twitter.com/rtEQYtHQG0 Daniel J Drucker (@DanielJDrucker) June 6, 2024 Investigational GLP-1 medicines in the clinic Late-stage investigational GLP-1 medicines for type 2 diabetes and obesity include new molecules like retatrutide and orforglipron, showing potential differentiation from semaglutide and tirzepatide through better tolerability, greater weight loss, Hb A 1c reduction, and targeted outcomes
The most common side effects are gastrointestinal: nausea, fullness, constipation, diarrhea, reflux, and reduced appetite
SjholmKSvenssonPATaubeMJacobsonPAndersson-AssarssonJCCarlssonLMSet al
Clinicians may review your symptoms, adjust your dose progression, or recommend dietary and lifestyle changes
This creates a positive feedback loop that can further promote health improvements